1,932 reports of this reaction
1.3% of all DICLOFENAC POTASSIUM, FILM COATED reports
#18 most reported adverse reaction
HEPATIC ENZYME INCREASED is the #18 most commonly reported adverse reaction for DICLOFENAC POTASSIUM, FILM COATED, manufactured by Advagen Pharma Ltd. There are 1,932 FDA adverse event reports linking DICLOFENAC POTASSIUM, FILM COATED to HEPATIC ENZYME INCREASED. This represents approximately 1.3% of all 153,821 adverse event reports for this drug.
Patients taking DICLOFENAC POTASSIUM, FILM COATED who experience hepatic enzyme increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATIC ENZYME INCREASED is a less commonly reported adverse event for DICLOFENAC POTASSIUM, FILM COATED, but still significant enough to appear in the safety profile.
In addition to hepatic enzyme increased, the following adverse reactions have been reported for DICLOFENAC POTASSIUM, FILM COATED:
The following drugs have also been linked to hepatic enzyme increased in FDA adverse event reports:
HEPATIC ENZYME INCREASED has been reported as an adverse event in 1,932 FDA reports for DICLOFENAC POTASSIUM, FILM COATED. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATIC ENZYME INCREASED accounts for approximately 1.3% of all adverse event reports for DICLOFENAC POTASSIUM, FILM COATED, making it a notable side effect.
If you experience hepatic enzyme increased while taking DICLOFENAC POTASSIUM, FILM COATED, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.